Compare Orchid Chemicals with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs BIOCON - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD BIOCON ORCHID PHARMA LTD/
BIOCON
 
P/E (TTM) x -0.5 23.0 - View Chart
P/BV x 0.1 3.1 3.9% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 ORCHID PHARMA LTD   BIOCON
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
BIOCON
Mar-18
ORCHID PHARMA LTD/
BIOCON
5-Yr Chart
Click to enlarge
High Rs1941,188 16.3%   
Low Rs35305 11.5%   
Sales per share (Unadj.) Rs276.568.7 402.3%  
Earnings per share (Unadj.) Rs-79.27.6 -1,048.9%  
Cash flow per share (Unadj.) Rs-43.514.0 -311.0%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.1 0.0%  
Book value per share (Unadj.) Rs53.986.3 62.5%  
Shares outstanding (eoy) m70.45600.00 11.7%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x0.410.9 3.8%   
Avg P/E ratio x-1.498.9 -1.5%  
P/CF ratio (eoy) x-2.653.4 -4.9%  
Price / Book Value ratio x2.18.6 24.6%  
Dividend payout %013.2 0.0%   
Avg Mkt Cap Rs m8,067447,900 1.8%   
No. of employees `0002.86.1 45.5%   
Total wages/salary Rs m2,5279,311 27.1%   
Avg. sales/employee Rs Th6,956.16,705.8 103.7%   
Avg. wages/employee Rs Th902.51,514.2 59.6%   
Avg. net profit/employee Rs Th-1,993.0736.9 -270.5%   
INCOME DATA
Net Sales Rs m19,47741,234 47.2%  
Other income Rs m4072,062 19.7%   
Total revenues Rs m19,88443,296 45.9%   
Gross profit Rs m1,1038,291 13.3%  
Depreciation Rs m2,5193,851 65.4%   
Interest Rs m5,227615 849.9%   
Profit before tax Rs m-6,2365,887 -105.9%   
Minority Interest Rs m20213 9.2%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1251,569 -8.0%   
Profit after tax Rs m-5,5804,531 -123.2%  
Gross profit margin %5.720.1 28.2%  
Effective tax rate %2.026.7 7.5%   
Net profit margin %-28.711.0 -260.7%  
BALANCE SHEET DATA
Current assets Rs m11,01441,486 26.5%   
Current liabilities Rs m32,06021,413 149.7%   
Net working cap to sales %-108.148.7 -222.0%  
Current ratio x0.31.9 17.7%  
Inventory Days Days9564 148.3%  
Debtors Days Days3494 35.6%  
Net fixed assets Rs m29,44050,661 58.1%   
Share capital Rs m7053,000 23.5%   
"Free" reserves Rs m2,04348,808 4.2%   
Net worth Rs m3,80051,808 7.3%   
Long term debt Rs m9,01817,898 50.4%   
Total assets Rs m46,51099,897 46.6%  
Interest coverage x-0.210.6 -1.8%   
Debt to equity ratio x2.40.3 687.0%  
Sales to assets ratio x0.40.4 101.5%   
Return on assets %-0.85.2 -14.8%  
Return on equity %-146.98.7 -1,679.1%  
Return on capital %-3.79.6 -38.8%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51312,058 62.3%   
Fx outflow Rs m5,6497,348 76.9%   
Net fx Rs m1,8654,710 39.6%   
CASH FLOW
From Operations Rs m1,6826,621 25.4%  
From Investments Rs m-9,860-6,840 144.2%  
From Financial Activity Rs m6,644-2,397 -277.2%  
Net Cashflow Rs m-1,535-2,612 58.8%  

Share Holding

Indian Promoters % 32.3 40.4 80.0%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 4.6 8.4 54.8%  
FIIs % 3.3 10.7 30.8%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 19.9 277.9%  
Shareholders   84,811 109,995 77.1%  
Pledged promoter(s) holding % 54.9 0.0 137,300.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT  GSK PHARMA  PANACEA BIOTECH  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS